Bayer: results of a study for Adempas

(CercleFinance.com) - Bayer has announces that the Phase IV study of Adempas (riociguat) has reached its primary endpoint in PAH patients after an inadequate response to PDE5 inhibitors.


The results of the REPLACE randomised, controlled and open-label study included results from 226 patients with pulmonary arterial hypertension (PAH).

41% of patients switching to Adempas achieved the composite primary endpoint of clinical improvement in the absence of clinical worsening.


Copyright (c) 2020 CercleFinance.com. All rights reserved.